Hot Stocks to Watch roundup, featuring Locafy, Cyngn, VENU, Hims & Hers, Bone Biologics, and INmune Bio

June 27, 2025

DENVER, Colo., Jun 27, 2025 (247marketnews.com)- Locafy (NASDAQ:LCFY) recently unveiled its 2025 product roadmap showcasing AI-powered publishing and syndication tools designed to accelerate local SEO growth. Now, it’s collaborating with a leading U.S. reputation and review platform to syndicate optimized business listings, starting with real estate, mortgage brokers, and professional services, while overlaying AI search and engagement tools.

Cyngn’s (NASDAQ:CYN) stock skyrocketed after unveiling a strategic partnership with NVIDIA to integrate its Isaac robotics platform into Cyngn’s autonomous industrial vehicles, boosting scalability and safety. The firm also raised funds via a stock and warrant sale at $5.01/share, planning to deploy the capital toward working tech and growth.

Venu (NYSE:VENU) continues to reshape live entertainment through lucrative public-private partnerships (PPP). CEO J.W. Roth highlighted progress on its luxury amphitheater pipeline, including 20,000-seat McKinney and Broken Arrow venues, all supported by municipal incentives. VENU is targeting $200M just from its 2025 Luxe Suite sales and has $15 analyst price targets from Northland and ThinkEquity, which is inline with Aramark’s (NYSE:ARMK) $10.25M investment in VENU. Fittingly, Billboard teamed with VENU for a new “Disrupter” award.

Hims & Hers (NYSE:HIMS) is on a fast track globally. After proposing a $450M convertible notes offering to fuel AI and expansion, the company secured UK-based Zava for a European push. However, its U.S. reputation took a hit: Novo Nordisk cut ties over compounded GLP‑1 drug sales, triggering a drop in its share price. Still, Q1 revenue doubled to $586M with rising subscriber growth.

Bone Biologics (NASDAQ:BBLG) filed a patent application with the USPTO covering its rhNELL‑1 bone regeneration protein, potentially bolstering its IP and pipeline in spinal fusion, trauma, and osteoporosis markets. The move shows commitment to clinical development. Following this news, the company also regained compliance with Nasdaq’s minimum bid rule, stabilizing its listing status and investor access.

INmune Bio (NASDAQ:INMB) is hosting a conference call on Monday, June 30, at 8:00am EDT to present top line Phase 2 MINDFuL trial in early Alzheimer’s Disease data.

Please go to https://247marketnews.com/venu-disclosure/ for additional 247marketnews.com VENU disclosure.

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (LCFY, CYN, VENU, HIMS, BBLG, INMB)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.